#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group vs 11.1 months in the placebo ...
1. Response to treatment was noted in 33% of the high-grade glioma cohort and 69% of the low-grade cohort. 2. ...
1. Treatment with herpes simplex virus type 1 oncolytic virotherapy was shown not to demonstrate serious adverse events in pediatric ...
1. Carboplatin, given through intracerebral, convection-enhanced delivery, may be a viable adjunct in recurrent high-grade glioma treatment. Evidence Rating Level: 1 ...
1. In grade 2 glioma patients younger than 40 years old that have undergone subtotal tumour resection, or in patients ...
1. Analysis of genomewide data revealed three robust, nonoverlapping, and clinically significant tumor classes based on presence of IDH mutation ...
1. Hormonal contraception use was more prevalent among women who developed glioma, a brain tumor, to women without glioma. 2. ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.